Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- SEIU Local 2“Kevin Quinn: Hold Dexterra Accountable”: SEIU Local 2 holds rally outside TransLink officeSkyTrain cleaners employed by Dexterra Group have been sounding the alarm about serious safety concerns about their jobs over the last several months. TransLink has refused to meet the workers despite repeated requests. Now, WorkSafeBC inspections have backed up workers’ concerns, with reports outlining several health and safety violations that are still outstanding.
- CodoxoCodoxo Named a Winner in 2026 Fierce AI Innovation AwardsAI-powered Point Zero Payment Integrity recognized for helping health plans prevent payment errors before claims are created. — Codoxo, the leading provider of AI and generative AI-powered healthcare payment integrity solutions, today announced...
- Dianthus Therapeutics, Inc. NEW YORK andDianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on September 1, 2026, to four newly-hired, non-executive employees. The inducement grants were approved by the Company's independent Compensation Committee and were made as material inducements to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4).
- NanochonNanochon Performs First Case in the Chondrograft™ First in Human Clinical StudyNanochon, a medical device company developing Chondrograft™, a novel 3D-printed patented implant for the treatment of articular cartilage defects of the knee, today announced the successful treatment of the first patient in its First-in-Human (FIH)...
- Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that, in connection with the appointment of Jason V. O’Byrne as Chief Financial Officer effective August 11, 2026, the Company granted Mr. O’Byrne an employment inducement award consisting of stock options to purchase 650,000 shares of the Company’s common stock, with an effective grant date of September 1, 2026 and an exercise price of $10.56 per share, equal to the last reported sale price of the Company's common stock as reported by Nasdaq on September 1, 2026. The award was approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan. The stock options vest over four years, with 25 percent vesting on August 11, 2027 and the remainder vesting in 36 equal monthly installments over the following three years, subject to continuous employment as of such vesting dates.
- Xilio Therapeutics, Inc.Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective September 1, 2026, the company granted non-qualified stock options to purchase 19,865 shares of its common stock to two new employees under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan.
- Kaplan Fox & Kilsheimer LLP Alerts Hims & Hers Health, Inc. (NYSE: HIMS) Investors to a Securities Class Action Deadline on November 2, 2026Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) on behalf of investors.
- HIMS CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Hims & Hers Health, Inc. and Encourages Investors to Contact the FirmBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Hims To Contact Him Directly To Discuss Their Options
- Waterfall ScientificWaterfall Scientific Awarded Up to $54.5 Million from ARPA-H to Lead Consortium Developing Continuous-Flow Cell-Free mRNA Manufacturing and Characterization PlatformWORCESTER, Mass., September 02, 2026--Waterfall Scientific, a biotechnology company pioneering continuous-flow RNA manufacturing technologies, today announced that it has been selected by the Advanced Research Projects Agency for Health (ARPA-H) to lead a six-company consortium under the Genetic Medicines and Individualized Manufacturing for Everyone (GIVE) program. The project, titled ESCALATOR, brings together a network of industry leaders in cell-free nucleic acid synthesis, LNP formulation,
- $3M gift to transform emergency care for seniors through dedicated treatment spaceCompanies: 3MThe Westman Family Seniors’ Emergency Pod at Calgary’s South Health Campus will be the first of its kind in Western Canada
- Thyme CareThyme Care Closes $125+ Million Series E, Establishes Thyme Companies to Broaden Its Impact Across the Oncology EcosystemMorgan Health, CVS Health Ventures, and Humana, alongside other strategic payers and providers, invest in Thyme Care at a valuation of more than $2B The new capital accelerates Thyme Care's continued growth and establishes Thyme Companies, a newly formed parent entity building a broader...
- Community Health Systems, Inc.Community Health Systems to Participate in the Wells Fargo 21st Annual Healthcare ConferenceCompanies: Community Health SystemsFRANKLIN, Tenn., September 02, 2026--Community Health Systems, Inc. (NYSE:CYH) today announced that management will participate in the Wells Fargo 21st Annual Healthcare Conference to be held September 8-10, 2026.